High performance drug discovery: an operating model for a new era, 2001. ,
Gene expression profiling in psoriatic scalp hair follicles :clobetasol propionate shampoo 0.05% normalizes psoriasis disease markers.European Academy of Dermatology and Venerology, 2010. ,
Optimal concentration of tacalcitol in once-daily treatment of psoriasis, Journal of Dermatological Treatment, vol.51, issue.3, pp.145-150, 1990. ,
DOI : 10.2337/diab.41.11.1491
The Development and Characterization of an In Vitro Model of Psoriasis, Journal of Investigative Dermatology, vol.123, issue.5, pp.892-901, 2004. ,
DOI : 10.1111/j.0022-202X.2004.23435.x
Practical synopsis of cutaneous disease, according to the arrangement of Dr, 1836. ,
The Cost of Biopharmaceutical R&D: Is Biotech Different? Managerial and Decision Economics, pp.4-5469, 2007. ,
The price of innovation: new estimates of drug development costs, Journal of Health Economics, vol.22, issue.2, pp.151-185, 2003. ,
DOI : 10.1016/S0167-6296(02)00126-1
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs, Clinical Pharmacology & Therapeutics, vol.36, issue.3, pp.272-279, 2010. ,
DOI : 10.2174/138920108786786358
Integrated??Pharmacokinetics??and Pharmacodynamics in??Drug??Development, Clinical Pharmacokinetics, vol.57, issue.2, pp.713-737, 2007. ,
DOI : 10.2165/00003088-200746090-00001
The psoriasis bio-?assay for topical corticosteroid activity. Acta Dermato-?Venereologica, pp.43-48, 1972. ,
Objective Assessment of psoriasis lesion thickness for PASI Scoring using 3D Digital imaging, World Academy of science, Engineering and Technology, vol.63, 2010. ,
Patient Satisfaction with Psoriasis Therapies: An Update and Introduction to Biologic Therapy, Journal of Cutaneous Medicine and Surgery, vol.2, issue.Suppl 67, pp.310-330, 2004. ,
DOI : 10.1007/s10227-005-0030-6
Topical delivery of cosmetics and drugs. Molecular aspects of percutaneous absorption and delivery, European Journal of Dermatology, vol.19, issue.4, pp.309-332, 2009. ,
The Finite Dose Technique as a Valid in vitro Model for the Study of Percutaneous Absorption in Man, Current Problems in Dermatology, vol.7, pp.58-68, 1979. ,
DOI : 10.1159/000401276
Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring, Expert Opinion on Drug Metabolism & Toxicology, vol.39, issue.9, pp.1023-1038, 2009. ,
DOI : 10.2215/CJN.04010907
Epidemiology of Psoriasis, Current Drug Target -Inflammation & Allergy, vol.3, issue.2, pp.121-128496, 2004. ,
DOI : 10.2174/1568010043343958
OECD Guideline for the testing of chemicals: Skin Absorption: in-?vitro Method, p.428, 2004. ,
Translational dermatology in drug discovery: perspectives for integrating humanized xenograft models and experimental clinical studies, Drug Discovery Today, vol.13, issue.5-6, 2008. ,
DOI : 10.1016/j.drudis.2007.10.009
Skin biopsies for the measurmement of clinical pharmacodynamic biomarkers. Current opinion in biotechnology, pp.687-690, 2005. ,
Predicting human pharmacokinetics from preclinical data. Current opinion in drug discovery & Development, pp.100-111, 2004. ,
Identification of a Major Susceptibility Locus on Chromosome 6p and Evidence for Further Disease Loci Revealed by a Two Stage Genome-Wide Search in Psoriasis, Human Molecular Genetics, vol.6, issue.5, pp.813-820, 1997. ,
DOI : 10.1093/hmg/6.5.813
Drug development costs when financial risk is measured using the Fama-French three-factor model, Health Economics, vol.37, issue.Suppl. 3, 2009. ,
DOI : 10.1002/hec.1538
Translational Science in Medicine, International Journal of Pharmaceutical Medicine, vol.52, issue.5, pp.303-313, 2006. ,
DOI : 10.2165/00124363-200620050-00004
The FDA Critical Path Initiative and Its Influence on New Drug Development, Annual Review of Medicine, vol.59, issue.1, pp.1-12, 2008. ,
DOI : 10.1146/annurev.med.59.090506.155819